KPV vs LL-37

KPV wins for:

• Safety and side-effect profile (barely any, even long-term).
• Targeted cytokine suppression and inflammation control—excellent for gut, skin, and systemic flare.
• No pigment shift, HPTA interaction, or MCAS risk (unlike many other peptides).
• Simpler sourcing and stacking (pairs cleanly with BPC-157, TB-500, etc).

LL-37 wins for:

• Potent antimicrobial effects: active against bacteria, fungi, and viruses directly—covers infectious states KPV does not touch.
• Disrupting biofilms and persistent infections (nasal, soft tissues, cystic acne).
• Accelerated wound healing and angiogenesis—hands-down stronger here than KPV.
• Use cases where BPC-157 and TB-500 are too gentle or not broad enough.

KPV is your low-risk, go-to anti-inflammatory for gut and skin, especially for those sensitive to side effects. LL-37 brings the hammer for infection and stubborn wounds, but comes with higher risk of flaring underlying autoimmunity or inflammatory skin conditions.

Pick KPV if:

• You need a safe, daily anti-inflammatory for gut (IBD/IBS), systemic, or skin issues.
• Controlling on-cycle acne, redness, or rosacea without triggering pigment change or suppressing HPTA.
• You want to stack an anti-inflammatory with BPC-157 for complete healing coverage (remodel + cytokine control).
• You're prone to MCAS/histamine flares or sensitive skin reactions from other peptides.
• You want a long-term support peptide with essentially zero downtime or suppression worries.

Pick LL-37 if:

• You face stubborn or recurrent infections (respiratory, skin, sinus, or post-surgical) that haven't resolved with antibiotics.
• Need to break up biofilms protecting pathogens or to clear chronic Lyme, MRSA, or mold-exposure fallout.
• You want faster wound closure and regeneration after surgery, hair transplant, or injury.
• Topical use for cystic acne or stalled healing where other regenerative peptides weren't enough.
• You're experienced in peptide protocols and can monitor/mitigate flare risk (rosacea, psoriasis, general autoimmunity).